Brand Name

Ursodiol

Generic Name
Ursosiol
View Brand Information
FDA approval date: May 17, 2018
Form: Capsule

What is Ursodiol (Ursosiol)?

Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Efficacy and Safety of Oral Zinc Sulphate and Ursodeoxycholic Acid as Adjuvants to Phototherapy in Management of Neonatal Non-Hemolytic Unconjugated Hyperbilirubinemia
Efficacy and Safety of Oral Zinc Sulphate and Ursodeoxycholic Acid as Adjuvants to Phototherapy in Management of Neonatal Non-Hemolytic Unconjugated Hyperbilirubinemia
Enrollment Status: Recruiting
Publish Date: March 18, 2026
Intervention Type: Drug
Study Phase: Phase 4

Summary: Neonatal jaundice, or neonatal hyperbilirubinemia, is a common medical issue in the first two weeks of life, causing prolonged hospitalization and readmissions. It results from elevated total serum bilirubin (TSB) and is manifested as yellowish discoloration of the skin, sclera, and mucous membrane. Clinical jaundice appears in about 60% of term neonates and 80% of preterm infants within the first...

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)
Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)
Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

View All Clinical Trials

Related Latest Advances

The non-surgical therapy of uncomplicated gallbladder stones: is there a niche?
The non-surgical therapy of uncomplicated gallbladder stones: is there a niche?
Journal: Expert review of gastroenterology & hepatology
Published: April 15, 2026
Identification of primary sclerosing cholangitis: ICD-10 code validation and comparison with a large language model approach.
Identification of primary sclerosing cholangitis: ICD-10 code validation and comparison with a large language model approach.
Journal: Research square
Published: April 10, 2026
Impact of anti-gp210 and anti-centromere antibody dual positivity on clinical prognosis in patients with primary biliary cholangitis: risk analysis and establishment of response criteria
Impact of anti-gp210 and anti-centromere antibody dual positivity on clinical prognosis in patients with primary biliary cholangitis: risk analysis and establishment of response criteria
Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Published: April 09, 2026
View All Latest Advances